Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + fluorouracil + pertuzumab + trastuzumab
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen used primarily in the treatment of HER2-positive breast cancer. The regimen combines three chemotherapy agents (cyclophosphamide, epirubicin, and fluorouracil) with two monoclonal antibodies targeting HER2 (pertuzumab and trastuzumab). Cyclophosphamide is an alkylating agent that interferes with DNA replication; epirubicin is an anthracycline topoisomerase II inhibitor; fluorouracil is a pyrimidine analog antimetabolite. Pertuzumab and trastuzumab are both monoclonal antibodies that bind to different domains of the HER2 receptor, providing dual blockade to inhibit cancer cell growth and survival[1][4][5]. This combination aims to maximize efficacy by combining cytotoxic chemotherapy with targeted therapy.
- Other names
- CEF plus HPcyclophosphamide/epirubicin/fluorouracil plus pertuzumab/trastuzumab
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + fluorouracil + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + fluorouracil + pertuzumab + trastuzumab.